Professor Dyfrig Hughes

Athro mewn Ffarmacoeconomeg / Cyfarwyddwr Ymchwil

  1. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  2. Cyhoeddwyd

    Cost-effectiveness analysis of infliximab and adalimumab for Crohn's disease.

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 Ebr 2008.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  3. Cyhoeddwyd

    Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.

    Hughes, D., Hughes, D. A. & Dubois, D., 1 Ion 2004, Yn: Pharmacoeconomics. 22, 16, t. 1047-1059

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  4. Cyhoeddwyd

    Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis: Authors’ reply.

    Hughes, D., Culeddu, G., Plumpton, C., Wood, E., Dick, A. D., Beresford, M. W. & Ramanan, A. V., Maw 2019, Yn: Ophthalmology. 126, 3, t. e24-e25

    Allbwn ymchwil: Cyfraniad at gyfnodolynLlythyradolygiad gan gymheiriaid

  5. Cyhoeddwyd

    Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with Juvenile Idiopathic Arthritis

    Hughes, D. A., Culeddu, G., Plumpton, C. O., Wood, E., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot Lacassagne, S., Hardwick, B., Hickey, H., Woo, P., Beresford, M. W. & Ramanan, A. V., Maw 2019, Yn: Ophthalmology. 126, 3, t. 415-424

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  6. Cyhoeddwyd

    Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity

    Hughes, D., Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. & Pirmohamed, M., 1 Meh 2004, Yn: Pharmacogenetics. 14, 6, t. 335-342

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  7. Cyhoeddwyd

    Cost-Effectiveness of Pharmacogenetics-Guided Warfarin Therapy vs. Alternative Anticoagulation in Atrial Fibrillation

    Hughes, D., Pink, J., Pirmohamed, M., Lane, S. & Hughes, D. A., 23 Medi 2013, Yn: Clinical Pharmacology and Therapeutics.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  8. Cyhoeddwyd

    Cost-Effectiveness Analysis of the Use of Point-of-Care C-Reactive Protein Testing to Reduce Antibiotic Prescribing in Primary Care

    Holmes, E., Harris, S. D., Hughes, A., Craine, N. & Hughes, D., 7 Rhag 2018, Yn: Antibiotics. 7, 4, 19 t., 106.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  9. Cyhoeddwyd

    Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa

    Culeddu, G., Brogan, P. A. & Hughes, D., 2021.

    Allbwn ymchwil: Cyfraniad at gynhadleddAralladolygiad gan gymheiriaid

  10. Cyhoeddwyd

    Cost of non-compliance and non-persistence with medications for diabetes mellitus

    Hughes, D., Salas, M., Hughes, D. A., Lebmeier, M. & Vardeva, K., 1 Awst 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  11. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease.

    Hughes, D., Hughes, D. A., Marchetti, M. & Colombo, G., 1 Chwef 2005, Yn: Expert Review of Pharmacoeconomics and Outcomes Research. 5, 1, t. 29-38

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  12. Cyhoeddwyd

    Cost minimization of on-demand maintenance therapy with proton pump inhibitors in nonerosive gastroesophageal reflux disease

    Hughes, D. & Hughes, D. A., 1 Tach 2004, Yn: Value in Health. 7, 6, t. 753

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  13. Cyhoeddwyd

    Cost effectiveness of pharmacogenetic screening prior to initiation of carbamazepine treatment for epilepsy

    Plumpton, C. O., Yip, V., Alfirevic, A., Marson, A., Pirmohamed, M. & Hughes, D., Tach 2013, Yn: Value in Health. 16, 7, t. A624-A624

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  14. Cyhoeddwyd

    Cost effectiveness analysis of treatments for children with uncontrolled asthma symptoms despite taking inhaled corticosteroids

    Culeddu, G., Sinha, I., Donegan, S., Maden, M., Cividini, S., Rose, K., Fulton, O., Turner, S., Tudor-Smith, C. & Hughes, D., 27 Hyd 2023, Yn: European Respiratory Journal. 62 , Supplement 67, PA 523.

    Allbwn ymchwil: Cyfraniad at gyfnodolynCrynodeb Cyfarfodadolygiad gan gymheiriaid

  15. Cyhoeddwyd

    Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout

    Plumpton, C., Alfirevic, A., Pirmohamed, M. & Hughes, D., 1 Hyd 2017, Yn: Rheumatology. 56, 10, t. 1729-1739

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  16. Cyhoeddwyd

    Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis.

    Sorensen, S. V., Baker, T., Fleurence, R., Dixon, J., Roberts, C., Haider, S. & Hughes, D., 1 Awst 2009, Yn: International Journal of Tuberculosis and Lung Disease. 13, 8, t. 945-954

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  17. Cyhoeddwyd

    Core items for a standardized resource-use measure (ISRUM): expert Delphi consensus survey

    Thom, J., Brookes, S. T., Ridyard, C., Riley, R., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., Meh 2018, Yn: Value in Health. 21, 6, t. 640-649

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  18. Cyhoeddwyd

    Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey

    Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 Mai 2017, t. P265. 1 t.

    Allbwn ymchwil: Cyfraniad at gynhadleddMurlenadolygiad gan gymheiriaid

  19. Cyhoeddwyd

    Core Health Outcomes in Childhood Epilepsy (CHOICE): Development of a core outcome set using systematic review methods and a Delphi survey consensus

    Crudgington, H., Rogers, M., Bray, L., Carter, B., Currier, J., Gibbon, F., Hughes, D., Lyle, S., Roberts, D., Smith, C. T., Gringras, P., Pal, D. & Morris, C., Mai 2019, Yn: Epilepsia. 60, 5, t. 857-871

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  20. Cyhoeddwyd

    Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT

    Blair, J., McKay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., Gregory, J. W., Hughes, D. & Gamble, C., Awst 2018, Yn: Health Technology Assessment. 22, 42, t. 1-112 112 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  21. Cyhoeddwyd

    Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation

    Blair, J. C., McKay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., Gregory, J. W., Hughes, D. A. & Gamble, C., 3 Ebr 2019, Yn: British Medical Journal. 365, t. l1226 l1226.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  22. Cyhoeddwyd

    Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)

    Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Medi 2017, t. 22-23.

    Allbwn ymchwil: Cyfraniad at gynhadleddCrynodebadolygiad gan gymheiriaid

  23. Cyhoeddwyd

    Continuous Subcutaneous Infusion Versus Multiple Dose Injection of Insulin For Newly-Diagnosed T1D Paediatric Patients: A Cost-Utility Analysis

    Ridyard, C., Blair, J. & Hughes, D., 20 Hyd 2017, Yn: Value in Health. 20, 9, t. A582

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  24. Cyhoeddwyd

    Content of Health Economics Analysis Plans (HEAPs) for trial-based economic evaluations: expert Delphi consensus survey

    Thorn, J., Davies, C. F., Brookes, S., Noble, S., Dritsaki, M., Gray, E., Hughes, D., Mihaylova, B., Petrou, S., Ridyard, C., Sach, T., Wilson, E., Wordsworth, S. & Hollingworth, W., 1 Ebr 2021, Yn: Value in Health. 24, 4, t. 539-547 9 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  25. Cyhoeddwyd

    Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches

    Hughes, D., Charles, J. M., Dawoud, D. M., Edwards, R. T., Holmes, E. A., Jones, C. L., Parham, P., Plumpton, C., Ridyard, C. O., Lloyd-Williams, H., Wood, E. M. & Yeo, S., Mai 2016, Yn: Pharmacoeconomics. 34, 5, t. 447-461

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  26. Cyhoeddwyd

    Comparisons between the medication possession ratio (MPR) and gaps measures of medication compliance: are we selling ourselves short by relying on the MPR?

    Hughes, D., Nichol, M., Manias, E., Hughes, D. A. & Schabert, V. F., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  27. Cyhoeddwyd
  28. Cyhoeddwyd

    Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation

    Hughes, D., Pink, J., Pirmohamed, M. & Hughes, D. A., 25 Ebr 2013, Yn: Clinical Pharmacology and Therapeutics.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  29. Cyhoeddwyd

    Community views on factors affecting medicines resource allocation: Cross-sectional survey of 3080 adults in Australia

    Chim, L., Salkeld, G., Kelly, P., Lipworth, W., Hughes, D. & Stockler, M., 2019, Yn: Australian Health Review . 43, 3, t. 254-260

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  30. Cyhoeddwyd

    Combining model-based clinical trial simulation, pharmacoeconomics and value of information to optimize trial design

    Hill-McManus, D. & Hughes, D., Ion 2021, Yn: CPT: Pharmacometrics & Systems Pharmacology . 10, 1, t. 75-83 9 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  31. Cyhoeddwyd

    Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review

    Sinnappah, K. A., Stocker, S. L., Chan, J. S., Hughes, D. A. & Wright, D. F. B., 25 Meh 2022, Yn: International Journal of Pharmacy Practice. 30, 3, t. 215-225 11 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  32. Cyhoeddwyd

    Clinical and econnomic importance of completion of therapy in the treatment of LRTIs

    Hughes, D. & Hughes, D. A., 1 Medi 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  33. Cyhoeddwyd

    Clinical Pharmacology: Special safety considerations in drug development and pharmacovigilance.

    Hughes, D., Atuah, K. N., Hughes, D. A. & Pirmohamed, M., 1 Ion 2004, Yn: Drug Safety. 27, 8, t. 535-554

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  34. Cyhoeddwyd

    Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios

    Hughes, D., Parham, P. E. & Hughes, D. A., 16 Chwef 2015, Yn: Philosophical Transactions B: Biological Sciences. 370, 1665

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  35. Cyhoeddwyd

    Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: Pharmacoeconomic considerations.

    Hughes, D. & Hughes, D. A., 1 Gorff 2005, Yn: European Journal of Cancer. 41, 11, t. 1655

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  36. Cyhoeddwyd

    Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data

    Hill-McManus, D. & Hughes, D., Meh 2022, Yn: British Journal of Clinical Pharmacology. 88, 6, t. 2782-2792 11 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  37. Cyhoeddwyd

    Chiral chromatography: Costs of chiral switching.

    Hughes, D. & Hughes, D. A., 1 Ion 2008, Yn: Pharmaceutical Journal. 281, t. 213

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  38. Cyhoeddwyd

    Charitable contributions to funding cancer services for children and young people in England and Wales

    Hughes, D., Linck, P., Tunnage, B., Hughes, D. A. & Edwards, R. T., 1 Ion 2008, Yn: Journal of Child Health Care. 12, 2, t. 156-168

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  39. Cyhoeddwyd

    Changing Agendas on Sleep, Treatment and Learning in Epilepsy (CASTLE) Sleep-E: A protocol for a randomised controlled trial comparing an online behavioural sleep intervention with standard care in children with Rolandic epilepsy

    Al-Najjar, N., Bray, L., Carter, B., Collingwood, A., Cook, G., Crudgington, H., Dietz, K., Hardy, W., Hiscock, H., Hughes, D., Morris, C., Rouncefield-Swales, A., Saron, H., Spowart, C., Stibbs-Easton, L., Tudur Smith, C., Watson, V., Whittle, L., Wiggs, L., Wood, E., Gringas, P. & Pal, D. K., 10 Maw 2023, Yn: BMJ Open. 13, 3, e065769.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  40. Cyhoeddwyd

    Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

    Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Rhag 2012, Yn: Value in Health. 15, 8, t. 1162-1171

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  41. Cyhoeddwyd

    Challenges for economic evaluation of strategies to contain antimicrobial resistance

    Holmes, E. & Hughes, D., 27 Medi 2019, Yn: Antibiotics. 8, 4, 8 t., 166.

    Allbwn ymchwil: Cyfraniad at gyfnodolynSylw/Dadladolygiad gan gymheiriaid

  42. Cyhoeddwyd

    Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)

    Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Medi 2017.

    Allbwn ymchwil: Cyfraniad at gynhadleddMurlenadolygiad gan gymheiriaid

  43. Cyhoeddwyd

    Carer administration of as-needed sub-cutaneous medication for breakthrough symptoms in people dying at home: the CARiAD feasibility RCT

    Poolman, M., Roberts, J., Wright, S., Hendry, A., Goulden, N., Holmes, E., Byrne, A., Perkins, P., Hoare, Z., Nelson, A., Hiscock, J., Hughes, D., O'Connor, J., Foster, B., Reymond, L., Healy, S., Lewis, P., Wee, B., Johnstone, R. P., Roberts, R., Parkinson, A., Roberts, S. & Wilkinson, C., 2 Meh 2020, Yn: Health Technology Assessment. 24, 25, 150 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  44. Cyhoeddwyd

    CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children

    Harron, K., Mok, Q., Dwan, K., Ridyard, C., Mott, T., Millar, M., Ramnarayan, P., Tibby, S. M., Muller-Pebody, B., Hughes, D., Gamble, C. & Gilbert, R. E., Maw 2016, Yn: Health Technology Assessment. 20, 18

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  45. Cyhoeddwyd

    CARer-ADministration of as-needed subcutaneous medication for breakthrough symptoms in homebased dying patients (CARiAD): study protocol for a UK-based open randomised pilot trial

    Poolman, M., Roberts, J., Byrne, A., Perkins, P., Hoare, Z., Nelson, A., Hiscock, J., Hughes, D., Foster, B., O'Connor, J., Reymond, L., Healy, S., Roberts, R., Wee, B., Lewis, P., Johnstone, R., Roberts, S., Holmes, E., Wright, S., Hendry, A. & Wilkinson, C., 7 Chwef 2019, Yn: Trials. 20, 1, 16 t., 105.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  46. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  47. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  48. Cyhoeddwyd

    Biosimilars: Evidential standards for health technology assessment.

    Hughes, D. & Hughes, D. A., 1 Maw 2010, Yn: Clinical Pharmacology and Therapeutics. 87, 3, t. 257-261

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  49. Cyhoeddwyd

    Biological agents for the management of Crohn's disease in adults: a systematic review, meta-analysis and multiple treatment comparison

    Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Mai 2007.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  50. Cyhoeddwyd

    Biological agents for the management of Crohn's disease in adults: A systematic review, meta-analysis and multiples treatment comparison

    Hughes, D., Hughes, D. A., Kikuchi, T. & Bodger, K., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A147

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  51. Cyhoeddwyd

    Beyond registration: measuring the public health potential of new treatments for Malaria in Africa.

    Hughes, D., Lang, T., Hughes, D. A., Kanyok, T., Kengeya-Kayondo, J., Marsh, V., Haaland, A., Pirmohamed, M. & Winstanley, P., 1 Ion 2006, Yn: Lancet Infectious Diseases. 6, 1, t. 46-52

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  52. Cyhoeddwyd

    Between- and within-individual sociodemographic and psychological determinants of PrEP adherence among men who have sex with men prescribed a daily PrEP regimen in Wales

    Gillespie, D., de Bruin, M., Hughes, D., Ma, R., Williams, A., Wood, F., Couzens, Z., Jones, A. T. & Hood, K., Mai 2023, Yn: AIDS and Behavior. 27, 5, t. 1564-1572 9 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  53. E-gyhoeddi cyn argraffu

    Best step-up treatments for children with uncontrolled asthma: A systematic review and network meta-analysis of individual participant data

    Cividini, S., Sinha, I., Donegan, S., Maden, M., Rose, K., Fulton, O., Culeddu, G., Hughes, D., Turner, S. & Tudor-Smith, C., 26 Hyd 2023, (E-gyhoeddi cyn argraffu) Yn: European Respiratory Journal.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  54. Cyhoeddwyd

    Back to basics: what is the relationship between dose and duration of drug action?

    Hughes, D. & Hughes, D. A., 1 Mai 2006.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  55. Cyhoeddwyd

    Assessment, Determinants & Economics of Medication Compliance & Persistence Forum.

    Hughes, D., Hughes, D. A., Gwadry-Sridhar, F. & Manias, E., 1 Ion 2009.

    Allbwn ymchwil: Cyfraniad at gynhadleddPapur

  56. Cyhoeddwyd
  57. Cyhoeddwyd

    Assessing the association between compliance and therapeutic failure for antiretroviral drugs in HIV positive patients

    Hughes, D. & Hughes, D. A., 1 Ion 2007, Yn: Value in Health. 10, 3, t. A171

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  58. Cyhoeddwyd
  59. Cyhoeddwyd

    Appropriate design and reporting of superiority, equivalence and non-inferiority clinical trials incorporating a benefit risk assessment: the BRAINS study including expert workshop

    Totton, N., Julious, S., Coates, E., Hughes, D., Cook, J., Biggs, K., Hewitt, C., Day, S. & Cooke, A., Hyd 2023, Yn: Health Technology Assessment. 27, 20, 86 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  60. Cyhoeddwyd

    Approaches to pharmacoeconomic analysis

    Hughes, D., Hughes, D. A., Walley, T. (gol.), Haycox, A. (gol.), Boland, A. (gol.) & Breckenridge, A. (gol.), 1 Ion 2004, Pharmacoeconomics. 2004 gol. Adis International, t. 101-126

    Allbwn ymchwil: Pennod mewn Llyfr/Adroddiad/Trafodion CynhadleddPennod

  61. Cyhoeddwyd

    Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation

    Mallucci, C. L., Jenkinson, M. D., Conroy, E. J., Hartley, J. C., Brown, M., Dalton, J., Kearns, T., Moitt, T., Griffiths, M. J., Culeddu, G., Solomon, T., Hughes, D. & Gamble, C., 26 Hyd 2019, Yn: The Lancet. 394, 10208, t. 1530-1539 10 t.

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  62. Cyhoeddwyd

    An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes

    Hughes, D., Farmer, A., Hardeman, W., Hughes, D. A., Prevost, A. T., Kim, Y., Craven, A., Oke, J., Boase, S., Selwood, M., Kellar, I., Graffy, J., Griffin, S., Sutton, S. & Kinmonth, A. L., 5 Ebr 2012, Yn: BMC Family Practice. 13, 30

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  63. Cyhoeddwyd

    An agenda for UK clinical pharmacology Pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Meh 2012, Yn: British Journal of Clinical Pharmacology. 73, 6, t. 968-972

    Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

  64. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Assessment Report – Agalsidase alfa (Replagal)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  65. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Tipranavir (Aptivus).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  66. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Parathyroid hormone (Preotact)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  67. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Idursulfase (Elaprase)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  68. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Emtricitabine (Emtriva)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  69. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dexrazoxane (Savene)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  70. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Lymphoid blast CML and PH+ ALL.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  71. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Dasatinib (Sprycel®) Chronic, accelerated or blast phase CML.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  72. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Darunavir (Prezista)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  73. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  74. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  75. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  76. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  77. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  78. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  79. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  80. Cyhoeddwyd
  81. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  82. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  83. Cyhoeddwyd
  84. Cyhoeddwyd
  85. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  86. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  87. Cyhoeddwyd
  88. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  89. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  90. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  91. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2007, 2007 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  92. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  93. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  94. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  95. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  96. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2008, 2008 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  97. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  98. Cyhoeddwyd

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., N. V., 1 Ion 2009, 2009 gol. Unknown.

    Allbwn ymchwil: Llyfr/AdroddiadAdroddiad Comisiwn

  99. Cyhoeddwyd
  100. Cyhoeddwyd